Trial Profile
A Randomized, Double-Blind, Placebo-Controlled, Dose-Finding Study to Assess the Efficacy and Safety of CEP-1347 in Patients With Parkinson's Disease.
Status:
Discontinued
Phase of Trial:
Phase II/III
Latest Information Update: 14 Jul 2017
Price :
$35
*
At a glance
- Drugs CEP 1347 (Primary)
- Indications Parkinson's disease
- Focus Therapeutic Use
- Acronyms PRECEPT
- Sponsors Cephalon
- 08 Jun 2017 Results presented at the 21st International Congress of Parkinson's Disease and Movement Disorders
- 08 Jun 2017 Results of longitudinal analysis of PRECEPT and PPMI trials to estimate the degree of enrichment and impact of reduced dopamine transporter (DAT) binding as a biomarker on future trials, presented at the 21st International Congress of Parkinson's Disease and Movement Disorders
- 03 May 2012 Company (Teva Pharmaceutical Industries) added as reported by ClinicalTrials.gov.